SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

After plunging to as low as $0.2 on March 14, Agora Holdings Inc (OTCMKTS:AGHI) managed to found some ground and recouped its losses in successive trading sessions. But again that rally seems to be fizzled out with the stock moving close to $0.2 mark. In last trading session, the share price of Agora declined more than 17% to close the day at $0.215.

Dismal financials

In February, Agora Holdings did release numerous promising press releases. The problem is that news alone cannot boost the share price for long. Moreover, the market capitalization of around $37 million appears to be far stretched for the financials of the firm to support. For 3Q2015, Agora reported $0 in cash and $4982 in total assets. The net loss came at $117,000 while total liabilities were $248,000.

Despite being in an extremely depressing financial state in January, Agora decided to compensate $25,000 to Quality Stocks for over four months of advertising, marketing, branding, social media, and investor relations services.

The buzz

Quality Stocks is not the only entity trying to generate buzz around Agora. There is also a paid promotion that has been touting its stock for quite a while now. The landing page that was set up as part of this campaign has been removed and the minimal compensations revealed by the circulars alerts that the campaign is close to end.

Even if Agora stock is left to trade in absence of any campaign, the risks will continue to be significant. At the end of last September, the company reported nearly $138,000 in due convertible notes that permitted their owners to convert them into common shares at a price of $0.002. This conversion picture will get clear once the company releases its annual report for FY2015 at the end of this month.

SHARE
Previous articleContraVir Pharmaceuticals Inc (NASDAQ:CTRV) Skyrockets On Positive Hepatitis B Results
Next articleNocopi Technologies, Inc. (OTCMKTS:NNUP) Drawing Market’s Attention
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.